title: Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor.
abstract: IL-2 therapy is a potent inductive stimulus for nitric oxide (NO.) synthesis in mice and humans. It is not yet clear whether NO. can contribute to IL-2-induced therapeutic responses. The murine skin cancer Meth A is relatively resistant to lymphokine-activated killer (LAK) cell killing, allowing evaluation of the role of IL-2-induced NO. synthesis in vivo, without contribution by LAK cells. Subcutaneous IL-2 treatment of mice bearing i.p. Meth A tumor increased nitrite production by cells derived from ascites (63 +/- 14 microM vs 3.2 +/- 1.5 microM in untreated controls). N omega-monomethyl-L-arginine (MLA), NO. synthase inhibitor, prevented this increase. NO. production correlated in an inverse fashion with tumor cell proliferation in vitro. Evidence for IL-2-induced heme nitrosylation was demonstrated in tumor cells by electron paramagnetic resonance spectroscopy. By immunomagnetic depletion experiments, macrophages were implicated as a major source of NO. synthesis. Cytologic and flow-cytometric evaluation revealed that IL-2 treatment resulted in enhanced lymphocyte and macrophage recruitment into malignant ascites, and decreases in tumor cell recovery. MLA administration further increased host cell recovery. Subcutaneous IL-2 therapy increased urinary nitrate excretion up to eightfold in mice, and appeared to produce a significant survival advantage that was prevented by MLA administration.
authors.affiliation: Department of Internal Medicine (Hematology/Oncology), Chonbuk National University Medical School, Korea.
authors.forename: C Y
authors.initials: CY
authors.lastname: Yim
authors.forename: J R
authors.initials: JR
authors.lastname: McGregor
authors.forename: O D
authors.initials: OD
authors.lastname: Kwon
authors.forename: N R
authors.initials: NR
authors.lastname: Bastian
authors.forename: M
authors.initials: M
authors.lastname: Rees
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: J B
authors.initials: JB
authors.lastname: Hibbs
authors.forename: W E
authors.initials: WE
authors.lastname: Samlowski
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001201:Ascites / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D005260:Female; D007113:Immunity, Innate; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D019331:NG-Nitroarginine Methyl Ester; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000276:immunology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012878:Skin Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D009569:Nitric Oxide; D001120:Arginine; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester